Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3861-3866

  Hurst, Frank P ^a,b   Neff, Robert T ^a,b   Jindal, Rahul M ^a   Roberts, Jefferson R ^a,b   Lentine, Krista L ^c   Agodoa, Lawrence Y ^d   Abbott, Kevin C ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Calcineurin inhibitors; Renal transplantation; Rhabdomyolysis; USRDS

Indexed keywords

CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FOLLOW UP; GRAFT FAILURE; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICARE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR;

COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 71049160839     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp416     Document Type: Article

References (33)

1. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with sim-vastatin in a renal transplant patient. Am J Med 2000; 108: 351-352
2. Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others? Nephrol Dial Transplant 2001; 16: 873-874
3. Gumprecht J, Zychma M, Grzeszczak W et al. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. Med Sci Monit 2003; 9: CS89-CS91
4. Mora C, Rodŕiguez ML, Navarro JF. Cerivastatin-induced rhabdomy-olysis in a renal transplant on cyclosporin. Transplantation 2001; 72: 551
5. Rodŕiguez ML, Mora C, Navarro JF. Cerivastatin-induced rhabdomy-olysis. Ann Intern Med 2000; 132: 598
6. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-1179
7. Fontana I, Ginevri F, Basile G et al. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. Transplant Proc 2004; 36: 711-712
8. Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002; 90: 234-235
9. Arnadottir M, Eriksson LO, Thysell H et al. Plasma concentration profiles of simvastatin 3-hydroxyl-3-methylglutayl-coenzyme A re-ductase inhibitory activity in kidney transplant recipients with and without cyclosporine. Nephron 1993; 65: 410-413
10. Kasiske B, Cosio FG, Beto J et al. National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4(Suppl 7): 13-53
11. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2002; 163: 553-564
12. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther 1999; 24: 397-408
13. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41(Suppl 3): S1-S91
14. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002; 40: 638-643
15. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002; 2: 358-377
16. LawM,Rudnicka AR. Statin safety:asystematic review.Am J Cardiol 2006; 97(8A): 52C-60C
17. Antons KA, Williams CD, Baker SK et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-409
18. Kandus A, Kovac D, Cerne D et al. Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immuno-suppression: three-year experience. Transplant Proc 1998; 30: 1307-1309
19. Holdaas H, Fellström B, Jardine AG et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvas-tatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
20. Ichimaru N, Takahara S, Kokado Y et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417-423
21. Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5: 2236-2243
22. Renders L, Haas CS, Liebelt J et al. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. Br J Clin Pharmacol 2003; 56: 214-219
23. Eisenbach Ch, Pohl J, Dikow R et al. Severe rhabdomyolysis and renal failure triggered by a sauna visit in sickle cell trait: a case report. Clin Nephrol 2005; 63: 229-231
24. Kimmick G, Owen J. Rhabdomyolysis and hemolysis associated with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency. South Med J 1996; 89: 1097-1098
25. Sateriale M, Hart P. Unexpected death in a black military recruit with sickle cell trait: case report. Mil Med 1985; 150: 602-605
26. Wanner C, Krane V, März W et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
27. Winkelmayer WC, Schneeweiss S, Mogun H et al. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005; 46: 225-232
28. Kern EF, Maney M, Miller DR et al. Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes. Health Serv Res 2006; 41: 564-580
29. Korzets A, Gafter U, Dicker D et al. Levofloxacin and rhabdomyolysis in a renal transplant patient. Nephrol Dial Transplant 2006; 21: 3304-3305
30. Phanish MK, Krishnamurthy S, Bloodworth LL. Colchicine-induced rhabdomyolysis. Am J Med 2003; 114: 166-167
31. Segaert MF, De Soete C, Vandewiele I et al. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996; 11: 1846-1847
32. Wombolt DG, Jackson A, Punn R et al. Case report: rhabdomyoly-sis induced by mibefradil in a patient treated with cyclosporine and simvastatin. J Clin Pharmacol 1999; 39: 310-312
33. Abbott KC, Bucci JR, Cruess D et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002; 13: 2560-2569